Recently, Su et al. [123] reported a meta-analysis of the impact of BIM polymorphisms on the treatment effect of EGFR-TKIs among 14 trials, including 2649 patients with EGFR-mutated NSCLC who had been treated with EGFR-TKIs, such as gefitinib, erlotinib, and afatinib. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.